PARP1 and cancer: In particular inhibitors to DNA-PKs (NHEJ), RAD51 (HR), PARP1/2 (HR, altNHEJ, BER), CHK2 (HR, altNHEJ), CHK1 (HR, NER) are currently under clinical investigation in various cancers[16, 34].